Nordstrom Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $17.64 billion. The enterprise value is $33.02 billion.
Important Dates
The last earnings date was Wednesday, July 30, 2025, before market open.
Earnings Date | Jul 30, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 1.25% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.15B |
Shares Change (YoY) | +1.25% |
Shares Change (QoQ) | +0.17% |
Owned by Insiders (%) | 0.42% |
Owned by Institutions (%) | 78.48% |
Float | 1.14B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 5.90 |
PS Ratio | 1.05 |
Forward PS | 1.32 |
PB Ratio | 2.58 |
P/TBV Ratio | n/a |
P/FCF Ratio | 19.82 |
P/OCF Ratio | 12.69 |
PEG Ratio | 0.84 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 7.30, with an EV/FCF ratio of 37.11.
EV / Earnings | n/a |
EV / Sales | 1.99 |
EV / EBITDA | 7.30 |
EV / EBIT | 9.44 |
EV / FCF | 37.11 |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 2.57.
Current Ratio | 1.06 |
Quick Ratio | 0.48 |
Debt / Equity | 2.57 |
Debt / EBITDA | 3.76 |
Debt / FCF | 19.71 |
Interest Coverage | 3.59 |
Financial Efficiency
Return on equity (ROE) is -2.42% and return on invested capital (ROIC) is 8.77%.
Return on Equity (ROE) | -2.42% |
Return on Assets (ROA) | 5.37% |
Return on Invested Capital (ROIC) | 8.77% |
Return on Capital Employed (ROCE) | 12.38% |
Revenue Per Employee | $451,480 |
Profits Per Employee | -$4,263 |
Employee Count | 36,830 |
Asset Turnover | 0.41 |
Inventory Turnover | 2.26 |
Taxes
In the past 12 months, Teva Pharmaceutical has paid $94.00 million in taxes.
Income Tax | 94.00M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.76% in the last 52 weeks. The beta is 0.60, so Teva Pharmaceutical's price volatility has been lower than the market average.
Beta (5Y) | 0.60 |
52-Week Price Change | -11.76% |
50-Day Moving Average | 16.85 |
200-Day Moving Average | 17.28 |
Relative Strength Index (RSI) | 35.20 |
Average Volume (20 Days) | 12,391,498 |
Short Selling Information
Short Interest | 53.42M |
Short Previous Month | 40.00M |
Short % of Shares Out | 4.68% |
Short % of Float | n/a |
Short Ratio (days to cover) | 5.24 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $16.63 billion and -$157.00 million in losses. Loss per share was -$0.14.
Revenue | 16.63B |
Gross Profit | 8.25B |
Operating Income | 3.50B |
Pretax Income | 131.00M |
Net Income | -157.00M |
EBITDA | 4.52B |
EBIT | 3.50B |
Loss Per Share | -$0.14 |
Full Income Statement Balance Sheet
The company has $2.16 billion in cash and $17.54 billion in debt, giving a net cash position of -$15.38 billion or -$13.41 per share.
Cash & Cash Equivalents | 2.16B |
Total Debt | 17.54B |
Net Cash | -15.38B |
Net Cash Per Share | -$13.41 |
Equity (Book Value) | 6.83B |
Book Value Per Share | 5.95 |
Working Capital | 759.00M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was $1.39 billion and capital expenditures -$500.00 million, giving a free cash flow of $890.00 million.
Operating Cash Flow | 1.39B |
Capital Expenditures | -500.00M |
Free Cash Flow | 890.00M |
FCF Per Share | $0.78 |
Full Cash Flow Statement Margins
Gross margin is 49.60%, with operating and profit margins of 21.05% and -0.94%.
Gross Margin | 49.60% |
Operating Margin | 21.05% |
Pretax Margin | -0.41% |
Profit Margin | -0.94% |
EBITDA Margin | 27.20% |
EBIT Margin | 21.05% |
FCF Margin | 5.35% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.25% |
Shareholder Yield | -1.25% |
Earnings Yield | -0.89% |
FCF Yield | 5.04% |
Dividend Details Analyst Forecast
The average price target for Teva Pharmaceutical is $24.71, which is 60.66% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $24.71 |
Price Target Difference | 60.66% |
Analyst Consensus | Strong Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
Last Split Date | Jul 1, 2004 |
Split Type | Forward |
Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.57 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.57 |
Piotroski F-Score | 6 |